Maria A. Rodriguez

发表

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.

R. Gascoyne, L. Sehn, Zheng Zhou, 2014, Blood.

Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL

Michael L. Wang, R. Davis, Maria A. Rodriguez, 2020, Leukemia & lymphoma.

Polysomy of chromosome 12 in 60 patients with non‐hodgkin's lymphoma assessed by fluorescence in situ hybridization: Differences between follicular and diffuse large cell lymphoma

Maria A. Rodriguez, M. Andreeff, F. Cabanillas, 1994, Genes, chromosomes & cancer.

Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.

Terry L. Smith, Maria A. Rodriguez, P. Mclaughlin, 2002, Blood.

Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma

Maria A. Rodriguez, Y. Oki, F. Turturro, 2018, Leukemia & lymphoma.

High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex.

Zheng Zhou, A. Rademaker, L. Gordon, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase II trial of denileukin diftitox for relapsed/refractory T‐cell non‐Hodgkin lymphoma

Dan Jones, Maria A. Rodriguez, P. Mclaughlin, 2007, British journal of haematology.

Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B‐cell non‐Hodgkin lymphoma

Michael L. Wang, Maria A. Rodriguez, P. Mclaughlin, 2007, British journal of haematology.

Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes.

Terry L. Smith, Maria A. Rodriguez, P. Mclaughlin, 2003, Oncology reports.

Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.

Michael L. Wang, Maria A. Rodriguez, P. Mclaughlin, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma.

Michael L. Wang, Maria A. Rodriguez, S. Parmar, 2020, Blood advances.

Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma

Michael R. Green, Michael L. Wang, Maria A. Rodriguez, 2021, Blood.

CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity.

Michael L. Wang, Maria A. Rodriguez, C. Flowers, 2021, Blood advances.

Usage of erythropoiesis‐stimulating agents in cancer patients at an academic cancer center and experience with specific care management tools for anemia

Maria A. Rodriguez, A. Buzdar, A. Ferrajoli, 2011, Cancer.

Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen

Terry L. Smith, Maria A. Rodriguez, P. Mclaughlin, 2005, Cancer.

The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP.

Maria A. Rodriguez, P. Mclaughlin, A. Younes, 2013, Clinical lymphoma, myeloma & leukemia.

Second malignancies in patients with Hodgkin’s Lymphoma: Half a century of experience

Maria A. Rodriguez, A. Ng, C. Pinnix, 2022, Clinical and translational radiation oncology.

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma.

Maria A. Rodriguez, Y. Oki, Ying Yuan, 2012, Blood.

Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next‐generation sequencing approach

Maria A. Rodriguez, Y. Oki, V. Carlton, 2015, British journal of haematology.

Prospective phase II study of rituximab with alternating cycles of hyper‐CVAD and high‐dose methotrexate with cytarabine for young patients with high‐risk diffuse large B‐cell lymphoma

Michael L. Wang, Maria A. Rodriguez, Y. Oki, 2013, British journal of haematology.

Models of Survivorship Care

Maria A. Rodriguez, F. Zandstra, M. Rodriguez, 2015 .

Use of chemotherapy within the last 14 days of life in patients treated at a comprehensive cancer center.

Maria A. Rodriguez, Lee Cheng, A. Y. DeJesus, 2014, JAMA internal medicine.

Phase 2 trial of rituximab plus hyper‐CVAD alternating with rituximab plus methotrexate‐cytarabine for relapsed or refractory aggressive mantle cell lymphoma

Michael L. Wang, Maria A. Rodriguez, H. Kantarjian, 2008, Cancer.

Gallium Scan after the Second and Fourth Chemotherapy Cycle is Predictive in Aggressive Non-Hodgkin ’ s Lymphomas

Maria A. Rodriguez, D. Podoloff, P. Mclaughlin, 2012 .

Ethical Issues in Cancer Survivorship

Maria A. Rodriguez, G. Palos, Paula A. Lewis-Patterson, 2017 .

Long Term Follow-Up of Lenalidomide and Rituximab as Initial Treatment of Follicular Lymphoma.

Michael L. Wang, Maria A. Rodriguez, P. Jain, 2020, Blood.

Ultra–low‐dose radiotherapy for definitive management of ocular adnexal B‐cell lymphoma

Michael L. Wang, Maria A. Rodriguez, Y. Oki, 2018, Head & neck.

Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma*

Maria A. Rodriguez, Y. Oki, K. Young, 2017, Leukemia & lymphoma.

Second Malignancies After Chemotherapy and Radiotherapy for Hodgkin Disease

Maria A. Rodriguez, L. Levy, E. Atkinson, 2004, American journal of clinical oncology.

High ten‐year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R‐FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study

Michael L. Wang, Maria A. Rodriguez, Y. Oki, 2017, British journal of haematology.

Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma.

Michael R. Green, Maria A. Rodriguez, E. Shpall, 2020, Blood advances.

Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma

Maria A. Rodriguez, P. Mclaughlin, S. Neelapu, 2020, Leukemia & lymphoma.

Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma.

Michael L. Wang, Maria A. Rodriguez, Y. Oki, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma.

Maria A. Rodriguez, S. Tucker, P. Mclaughlin, 2003, International journal of radiation oncology, biology, physics.

Long-Term F ollow-Up o f a P rospective S tudy o f C ombined Modality T herapy f or S tage I -II I ndolent N on-Hodgkin's Lymphoma

Maria A. Rodriguez, L. Fuller, P. Mclaughlin, 2003 .

NCCN preliminary non-Hodgkin's lymphoma practice guidelines.

J. Vose, A. Zelenetz, Maria A. Rodriguez, 1997, Oncology.

Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma

Maria A. Rodriguez, P. Mclaughlin, A. Younes, 2006, Leukemia & lymphoma.

Transformed non‐Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database

L. Gordon, A. LaCasce, Allison Crosby-Thompson, 2013, British journal of haematology.

Primary cutaneous B-cell lymphoma (non-leg type) has excellent outcomes even after very low dose radiation as single-modality therapy

Christine F. Wogan, Maria A. Rodriguez, P. Allen, 2016, Leukemia & lymphoma.

Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma

Maria A. Rodriguez, C. Flowers, L. Fayad, 2020, Leukemia & lymphoma.

Follicular large cell lymphoma: An aggressive lymphoma that often presents with favorable prognostic features

Maria A. Rodriguez, P. Mclaughlin, F. Cabanillas, 1999 .

Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas

Maria A. Rodriguez, P. Mclaughlin, F. Cabanillas, 2012, Leukemia & lymphoma.

Sphingosomal vincristine in CHOP is a promising new treatment for elderly, as well as poor prognosis patients with aggressive non-Hodgkin's lymphoma (NHL): Follow-up results of a phase II study

Maria A. Rodriguez, F. Cabanillas, N. Dang, 2004 .